An interventional study of Oral care programme in Head and Neck Cancer, sponsored by Göteborg University. Recruiting at 2 sites in Sweden. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-04-20.
Sponsored by Göteborg University · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies in Head and Neck Neoplasms with a site in Sweden — 10 open to participants now, 13 under way, 2 of them phase 3. Head and Neck Neoplasms · Sweden.
Among the 34 studies in Head and Neck Neoplasms with a site in Sweden, this one is the 14th largest by planned enrollment of the 26 interventional ones that give a count, is one of 2 that started in 2018, is one of 9 with no phase, reaches primary completion later than 5 of the 12 other live ones, and was the 13th registered.
2,713 studies on the registry are indexed under Head and Neck Neoplasms; 596 are open to participants now.
Browse Head and Neck Neoplasms studies →10 of the 34 studies in Head and Neck Neoplasms with a site in Sweden are open now. Recruiting first, the newest first:
Region Skane · Sites in Sweden
Ages 18+
OncoZenge AB · Sites in Sweden, Denmark, Germany and 1 more country
Ages 18–80
Karolinska University Hospital · Sites in Sweden
Ages 18+
Uppsala University · Sites in Sweden
Ages 18+
Lars Olaf Cardell · Sites in Sweden
Ages 18+
A study can be open while its sites in Sweden have not opened yet or have stopped. Only those recruiting at a site in Sweden →
Of the 453 Head and Neck Neoplasms studies recruiting now, 345 (76%) set no upper age limit and 51 (11%) stop at 75 or younger; 21 take children under 18; 27 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 3 · Phase 3 10 · Phase 4 2
First in 2003; this study’s year is marked. 2 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 150 is above the median of 46 across 2,033 interventional studies indexed under Head and Neck Neoplasms.
Median enrollment 187 across the 26 interventional studies, 119 across the 8 observational. Of the 20 that completed or were terminated, 9 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 34 have an industry lead sponsor. The 10 most frequent:
Göteborg University is the lead sponsor of 271 studies on the registry; 46 are open to participants now.
Göteborg University has 2 studies filed under Head and Neck Neoplasms — fewer than ten, so there is no comparison to draw.
3 of the studies in Head and Neck Neoplasms with a site in Sweden that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07672236Phase 3OncoZenge ABA Clinical Study to Compare BupiZenge With Lidocaine for Pain Due to Oral Mucositis in Patients With Head and Neck Cancer. | 2026-12-23 |
| NCT03481647Göteborg UniversityEvaluation of an Oral Care Programme for Head and Neck Cancer Patients | 2026-12-31 |
| NCT06639191Karolinska University Hospital[177Lu]Lu-AKIR001 First-in-human Study | 2027-11-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 34 studies in Head and Neck Neoplasms with a site in Sweden, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will evaluate the effect of an intensified oral care programme on prevalence, severity and duration of mucositis in patients undergoing treatment for cancer in the head and neck region.
Patients in the control group get professional oral care once a week.
This study will evaluate the effect of an oral care programme on prevalence, severity and duration of mucositis in patients undergoing treatment for cancer in the head and neck region. The oral care programme consists of professional oral care and swabbing of the mucosal membranes with a saline/bicarbonate solution once a week. The patients are instructed to rinse with a saline/bicarbonate solution 5 times per day. They are given an oral care diary to help them keep track of their daily oral hygiene measures and rinses. Repeated oral hygiene instructions are given if needed.
Patients in the control group get professional oral care once a week.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The intervention consists of professional oral care and swabbing of the mucosal membranes with a saline and bicarbonate solution, five daily rinses with a saline and bicarbonate solution, a diary to register oral care measures and rinses
Procedure: Oral care programme
Professional oral care once a week according to existing routine
Professional oral care (dental hygienist), intensified oral care measures by the patient
Oral mucositis
Reduced incidence of clinical mucositis assessed using Oral Mucositis Assessment Scale (9 areas in the mouth are examined and signs of ulceration are scored; 0=no lesion,1= lesion \<1cm2, 2=lesion 1-3 cm2, 3=lesion \> 3 cm2 as well as erythema, which is scored as follows: 0=no erythema, 1= mild erythema and 2=severe erythema. Total score for ulceration can vary from 0-27 and for erythema from 0-18. Mucositis is present at scores ≥ 1.)
Time frame: First week of RT (mucositis score at one time-point)
Oral mucositis
Reduced incidence of clinical mucositis assessed using Oral Mucositis Assessment Scale (9 areas in the mouth are examined and signs of ulceration are scored; 0=no lesion,1= lesion \<1cm2, 2=lesion 1-3 cm2, 3=lesion \> 3 cm2 as well as erythema, which is scored as follows: 0=no erythema, 1= mild erythema and 2=severe erythema. Total score for ulceration can vary from 0-27 and for erythema from 0-18. Mucositis is present at scores ≥ 1.)
Time frame: Second week of RT (mucositis score at one time-point)
Oral mucositis
Reduced incidence of clinical mucositis assessed using Oral Mucositis Assessment Scale (9 areas in the mouth are examined and signs of ulceration are scored; 0=no lesion,1= lesion \<1cm2, 2=lesion 1-3 cm2, 3=lesion \> 3 cm2 as well as erythema, which is scored as follows: 0=no erythema, 1= mild erythema and 2=severe erythema. Total score for ulceration can vary from 0-27 and for erythema from 0-18. Mucositis is present at scores ≥ 1.)
Time frame: Third week of RT (mucositis score at one time-point)
Oral mucositis
Reduced incidence of clinical mucositis assessed using Oral Mucositis Assessment Scale (9 areas in the mouth are examined and signs of ulceration are scored; 0=no lesion,1= lesion \<1cm2, 2=lesion 1-3 cm2, 3=lesion \> 3 cm2 as well as erythema, which is scored as follows: 0=no erythema, 1= mild erythema and 2=severe erythema. Total score for ulceration can vary from 0-27 and for erythema from 0-18. Mucositis is present at scores ≥ 1.)
Time frame: Fourth week of RT (mucositis score at one time-point)
Oral mucositis
Reduced incidence of clinical mucositis assessed using Oral Mucositis Assessment Scale (9 areas in the mouth are examined and signs of ulceration are scored; 0=no lesion,1= lesion \<1cm2, 2=lesion 1-3 cm2, 3=lesion \> 3 cm2 as well as erythema, which is scored as follows: 0=no erythema, 1= mild erythema and 2=severe erythema. Total score for ulceration can vary from 0-27 and for erythema from 0-18. Mucositis is present at scores ≥ 1.)
Time frame: Fifth week of RT (mucositis score at one time-point)
Oral mucositis
Reduced incidence of clinical mucositis assessed using Oral Mucositis Assessment Scale (9 areas in the mouth are examined and signs of ulceration are scored; 0=no lesion,1= lesion \<1cm2, 2=lesion 1-3 cm2, 3=lesion \> 3 cm2 as well as erythema, which is scored as follows: 0=no erythema, 1= mild erythema and 2=severe erythema. Total score for ulceration can vary from 0-27 and for erythema from 0-18. Mucositis is present at scores ≥ 1.)
Time frame: Sixth week of RT (mucositis score at one time-point)
Not enrolling at this site.
Plan to share: No — We are not planning to make IPD available to researchers not involved in the project
No publications or documents are linked to this record.
Started Jan 2018 (actual). Primary completion is estimated for Dec 2026, 107 months after the start.
Of 437 non-industry interventional studies with no phase under Head and Neck Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 71. This study's planned 107 months is above that.
Counting every sponsor, half of 455 studies reached it within 33 months; a quarter within 18 and three quarters within 70.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.